SEGLENTIS is a unique co-crystal that contains 4 complementary mechanisms of analgesic and anti-inflammatory properties in 1 tablet1,2

Watch to see SEGLENTIS in action


SEGLENTIS is a unique, single-phase crystalline entity comprising celecoxib and tramadol hydrochloride in a 1:1 molecular and 1.27:1 weight ratio, unlike a standard fixed dose or coadministration of individual agents.

A unique network of key hydrogen bonds forms the SEGLENTIS co-crystal

SEGLENTIS leverages 4 complementary mechanisms of analgesia in the central and peripheral pathways1,2

The effect of celecoxib is believed to be due to3:


Inhibition of COX-2


The effect of celecoxib is
believed to be due to3:


Inhibition of COX-2


The effect of tramadol is believed to be due to4:


Weak inhibition of serotonin reuptake


Partial agonism of μ-opioid receptor


Weak inhibition of norepinephrine reuptake

The tramadol hydrochloride mechanism of action is not completely understood. The M1 metabolite is primarily responsible for the analgesic effect on the μ-opioid receptor.4

API, active pharmaceutical ingredient.

See the pharmacokinetic
data for SEGLENTIS1

Get important


  1. SEGLENTIS [prescribing information]. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; October 2021.
  2. Almansa C, Frampton CS, Vela JM, Whitelock S, Plata-Salamán CR. Co-crystals as a new approach to multimodal analgesia and the treatment of pain. J Pain Res. 2019;12:2679-2689. doi:10.2147/jpr.s208082.
  3. Celebrex (celecoxib capsules) [prescribing information]. New York, NY: Pfizer Inc.; April 2021.
  4. Ultram (tramadol hydrochloride) tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; September 2021.